Skip to main content

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Clinical Pharmacokinetics volume 58, pages 1351–1352 (2019)Cite this article

A Letter to the Editor to this article was published on 27 August 2019

The Original Article was published on 04 April 2019

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):827–33. https://doi.org/10.1007/s40262-019-00747-3(Epub 4 Apr 2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. FDA Guidance document “Statistical Approaches to Establishing Bioequivalence”. 2001. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence. Accessed 20 June 2019.

  3. ANSM Levothyrox public report. https://www.ansm.sante.fr/content/download/110115/1395469/version/1/file/Rapport+d%C3%A9valuation+bioequivalence+_+Levothyrox.pdf. Accessed 20 June 2019.

  4. ANSM: Contrôle de la nouvelle formule de Lévothyrox commercialisée à partir de mars 2017: note de synthèse 17-A-12th September 2017. file:///C:/Users/502264/Downloads/Rapport%20danalyse%20Agence%20(CTROL)%20_%20Levothyrox.pdf.

  5. Pharmacovigilance report: third report 6/7/2018 Comité technique de pharmacovigilance du 06/07/2018. http://www.ansm.sante.fr. Accessed 20 June 2019.

Download references

Author information

Authors and Affiliations

  1. Pharmacology, Clinical Research and Innovation Delegation, St Louis Hospital, Paris-Diderot University, Assistance Publique-Hôpitaux de Paris, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France

    Philippe Lechat

  2. Clinical Research Unit, Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

    Jacques Ropers

  3. Pharmacology and Toxicology, Centre Hospitalier Intercommunal de Créteil, Créteil, France

    Jérome Barré

  4. Internal Medicine, Paris-Diderot University, Groupe Hospitalier Lariboisière-Saint-Louis-Fernand-Widal, Paris, France

    Stephane Mouly

Authors
  1. Philippe Lechat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacques Ropers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jérome Barré
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephane Mouly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Lechat.

Ethics declarations

Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Philippe Lechat, Jacques Ropers, Jérome Barré, and Stephane Mouly declare that they have no potential conflicts of interest that might be relevant to the contents of this letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lechat, P., Ropers, J., Barré, J. et al. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 1351–1352 (2019). https://doi.org/10.1007/s40262-019-00814-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-019-00814-9